Galapagos Archives

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 9 Dec 2016

Galapagos gets another Milestone Payment from Gilead

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2016

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 2 May 2016

Galapagos and AbbVie expand their Cystic Fibrosis collaboration

Galapagos and AbbVie expand their ongoing collaboration in Cystic Fibrosis. With a growth in the portfolio, Galapagos’ milestones increase from €300M to €520M. The most famous collaboration between AbbVie (US) and Galapagos (Belgium) was perhaps their candidate for rheumatoid arthritis – which hit a reef in September, knocking Galapagos’ stock by 39%. But the less […]

May 2, 2016 - 2 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

polyganics microaire groningen medtech biotech neurosurgery

News and Trends 22 Jan 2016

Groningen’s MedTech Hub for Neurosurgery is Actually a Biotech Hotspot

I visited Groningen (Netherlands) and the University Medical centre there in November, and it was interesting to note the tight knit Biotechnology and medical research bubble which has been enlarging, now making multiple outbound research and clinical trial links to the US. One such example is Polyganics, which has signed an exclusive distribution agreement with its US strategic […]

January 22, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 30 Dec 2015

3 EU Biotechs which Over-performed in 2015

2015 was a crazy year for the Biotech industry, probably the craziest since the birth of the industry 40 years ago. I looked back on this year and here’s my personal top 3 of EU Biotechs which over-performed. I sorted them out in top partnerships, clinical trials and fundraising. (Of course, this lists is not […]

December 30, 2015 - 2 minutesmins - By Philip Hemme

Gilead galapagos abbvie filgotinib partner rheumatoid

News and Trends 18 Dec 2015

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie‘s shocking abandonment. The Mystery replacement partner has now been revealed as Gilead! Galapagos will receive an upfront payment of €670M from California’s Gilead, consisting of a license fee of €277M and a €393M equity investment in Galapagos. In addition, […]

December 18, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us